These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 22610925)
1. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925 [TBL] [Abstract][Full Text] [Related]
2. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607 [TBL] [Abstract][Full Text] [Related]
5. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382 [TBL] [Abstract][Full Text] [Related]
7. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636 [TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564 [TBL] [Abstract][Full Text] [Related]
9. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Howard A; Hoffman J; Sheth A Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830 [TBL] [Abstract][Full Text] [Related]
10. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523 [TBL] [Abstract][Full Text] [Related]
11. Voriconazole concentrations and outcome of invasive fungal infections. Miyakis S; van Hal SJ; Ray J; Marriott D Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos). Kline Y; Clemons KV; Woods L; Stevens DA; Tell LA Med Mycol; 2011 Jul; 49(5):500-12. PubMed ID: 21171838 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis). Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055 [TBL] [Abstract][Full Text] [Related]
14. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632 [TBL] [Abstract][Full Text] [Related]
15. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Przepiorka D; Buadi FK; McClune B Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475 [TBL] [Abstract][Full Text] [Related]
16. [Level of evidence for therapeutic drug monitoring of voriconazole]. Hulin A; Dailly E; Le Guellec C; Therapie; 2011; 66(2):109-14. PubMed ID: 21635857 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217 [TBL] [Abstract][Full Text] [Related]
18. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454 [TBL] [Abstract][Full Text] [Related]